1-3 of 3
Kouichi Ohshima
Close
Sort by
Journal Articles

Outcome of 136 Children with Advanced Lymphoblastic Lymphoma Receiving an BFM-Type Therapy with Intensified Maintenance: A Report from the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study

Shosuke Sunami, MD, PhD, Masahiro Sekimizu, MDPhD, Tetsuya Takimoto, MD,PhD, Tetsuya Mori, MD,PhD, Tetsuo Mitsui, MD, PhD, Reiji Fukano, MD, PhD, Takeshi Mori, MD, PhD, Atsushi Kikuta, MD PhD, Koh Katsuyoshi, MD,PhD, Toshihiko Imamura, MD, PhD, Akiko Moriya Saito, MD, PhD, Tomoyuki Watanabe, PhD, Kouichi Ohshima, MD, PhD, Junichiro Fujimoto, MD, PhD, Atsuko Nakazawa, MD, PhD, Ryoji Kobayashi, MD, PhD, Keizo Horibe, MD, Masahito Tsurusawa, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 3049.
https://doi.org/10.1182/blood.V124.21.3049.3049
Published: 2014
Journal Articles

HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines

Kenji Sugata, Yorifumi Satou, Jun-ichirou Yasunaga, Hideki Hara, Kouichi Ohshima, Atae Utsunomiya, Masao Mitsuyama, Masao Matsuoka
Journal: Blood
Blood (2012) 119 (2): 434–444.
https://doi.org/10.1182/blood-2011-05-357459
Published: 2012
Includes: Supplemental data
Journal Articles

The Synergistic Action of the microRNA-17 Cluster with c-MYC in Aggressive Cancer Development.

Hiroyuki Tagawa, MD, Kennoske Karube, MD, Shinobu Tsuzuki, MD, Kouichi Ohshima, MD, Masao Seto, MD
Journal: Blood
Blood (2006) 108 (11): 1415.
https://doi.org/10.1182/blood.V108.11.1415.1415
Published: 2006